Purpose. The insulin-like growth factor 1 receptor (IGF1R) is widely expressed in normal tissues and many malignancies in humans. We investigated the clinical significance of the expression of the IGF1R gene in human lung adenocarcinoma. Methods. A total of 238 patients with lung adenocarcinoma were investigated. Quantitative real-time reversetranscription polymerase chain reaction (RT-PCR) assays were performed to evaluate the gene expression of IGF1R, and immunohistochemical staining was done to evaluate the protein expression of IGF1R. Results. Among the 238 patients with lung adenocarcinoma, 107 tumors (45.0%) were IGF1R-low and 131 tumors (55.0%) were IGF1R-high. The IGF1R gene expression ratio was significantly lower in moderately to poorly differentiated adenocarcinomas than in well-differentiated adenocarcinomas (P = 0.0388). Gene expression of IGF1R was significantly correlated with protein expression of IGF1R (r = 0.7163, P \ 0.0001). Regarding patient survival, overall survival was significantly lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors (63.2% versus 76.1% 5-year survival, P = 0.0188). Multivariate analysis using a Cox proportional-hazards model demonstrated that IGF1R gene status was a significant prognostic factor predicting overall survival of patients with lung adenocarcinoma (hazard ratio 1.800; P = 0.0321). Moreover, the disease-free survival rate was significantly lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors (49.2% versus 64.6% 5-year survival, P = 0.0084).
Lung cancer is the leading cause of cancer death in many countries. Approximately 85% of lung cancer cases are categorized as non-small cell lung cancers (NSCLCs). Although various treatment options such as surgery, chemotherapy, and molecular-targeted therapy are available, the clinical outcome for NSCLC patients remains poor, and locoregional recurrence and distant metastases may develop even after complete resection by surgery in the early stage of the disease. 1 Therefore, it is important to clarify the biological characteristics of lung cancer to improve the clinical outcome of this disease. Recently, new developments in molecular biology have revealed that many molecules affect the biological behaviors of human malignant tumors, including tumor proliferation, tumor angiogenesis, metastasis, and chemo/radioresistance. Among these molecules, clinical studies have revealed that growth factors and/or their receptors can be used as biomarkers for diagnosing a patient or determining the likely progression of the disease. Moreover, these molecules can also be directly targeted for lung cancer therapy; for example, active mutations of the epidermal growth factor receptor (EGFR) gene occur in approximately 30% or more of lung adenocarcinomas in East Asia, and EGFR-specific tyrosine kinase inhibitors are effective for these cases. 2 In addition, vascular endothelial growth factor can induce tumor angiogenesis to promote tumor proliferation and metastasis, and an antibody against this factor, bevacizumab, has been reported to be clinically effective for treatment of lung adenocarcinoma. 3 These results suggest that it is important to clarify the clinical significance of other growth factors or their receptors in human lung adenocarcinoma.
The insulin-like growth factor 1 receptor (IGF1R) is a membrane receptor-type tyrosine kinase that is expressed in a variety of normal human tissues. 4 IGF1R is activated by two ligands, IGF-1 and IGF-2, and also by insulin at the supraphysiological level. Activation of IGF1R induces signal transductions via the phosphatidylinositol-3-kinase (PI3K)-AKT pathway and RAS/RAF/mitogen-activated protein kinase (MAPK) pathway. The PI3K-AKT pathway is associated with regulation of cell survival, and the RAS/ RAF/MAPK pathway is involved in regulation of cellular proliferation. 4, 5 As a result, IGF1R can regulate cellular metabolism, proliferation, and survival. IGF1R is widely expressed in many malignancies in humans, and its expression has been reported be involved in tumorigenesis. [6] [7] [8] [9] [10] In many malignancies, it is also reported that the crosstalk between EGFR and IGF1R signaling at multiple levels is associated with resistance against anti-EGFR therapy. [11] [12] [13] [14] [15] [16] [17] Furthermore, a number of IGF1R inhibitors are currently being investigated in clinical trials. 4, 5 However, only a few studies have investigated IGF1R expression in human lung cancer. [18] [19] [20] Therefore, we performed a clinical study on the expression of the IGF1R gene (IGF1R) in patients with lung adenocarcinoma in order to clarify its clinical significance.
PATIENTS AND METHODS

Patients
Consecutive lung adenocarcinoma patients who underwent surgery at the Department of Thoracic Surgery, Kyoto University Hospital from May 2001 to April 2005 were included in this study. This study was approved by the Ethics Committee of the Graduate School and Faculty of Medicine at Kyoto University, and informed consent was obtained in writing from all patients. Pathological tumornode-metastasis (TNM) staging was determined using the 7th tumor-node-metastasis classification system (International Union against Cancer). 21 The histological type and the grade of differentiation of the tumors were determined according to the classification system developed by the World Health Organization. 22 Quantitative Real-Time RT-PCR Tumor tissues were stored in RNAlater TissueProtect tubes (Qiagen K.K., Tokyo, Japan). Total RNA was extracted using the RNeasy Mini Kit (Qiagen K.K.), and (antisense primer), whose amplicon was 153 bp. The primers used to examine EGFR gene expression were: 5 0 -GGGAGTTGATGACCTTTGGA-3 0 (sense primer) and 5 0 -AACTTTGGGCGACTATCTGC-3 0 (antisense primer), whose amplicon was 169 bp. Expression of the b-actin gene was also evaluated as an internal control, using the following primers: 5 0 -GATCATTGCTCCTCCTGAGC-3 0 (sense primer) and 5 0 -AGTCCGCCTAGAAGCATTTG-3 0 (antisense primer), which amplified a 152 bp fragment. A 20 lL reaction mixture containing 10 lL Quantitect SYBR Green Master Mix (Qiagen K.K.), 0.5 lM of each primer, and 0.03 lg cDNA was prepared. PCR amplification was initiated by preincubation at 95°C for 15 min, followed by 50 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and elongation at 72°C for 35 s. The data were analyzed using the LightCycler analysis software program version 3.50 (Roche Diagnostics). The levels of IGF1R and EGFR expression for a given tumor sample were divided by the level of b-actin to obtain normalized expression ratios, which were expressed in permyriad.
Immunohistochemistry
A rabbit polyclonal antibody for IGF1Rb (#3027; Cell Signaling Technology, Danvers, MA) was used as a primary antibody for immunohistochemical (IHC) staining. All tumor tissues used in this study were derived from formalin-fixed pathologic samples taken from resected lung specimens. Fourmicron sections were cut from the paraffin-embedded blocks and mounted on glass slides. After the sections were deparaffinized in xylene and rehydrated with graded ethanol, they were heated in a microwave for 30 min in 10 mmol/L citrate buffer at pH 6.0 for antigen retrieval and cooled to room temperature for 20 min. Then, sections were immersed in methanol with 0.3% hydrogen peroxide for 30 min to inhibit exogenous peroxidase activity. After blocking nonspecific binding using 5% bovine serum albumin for 60 min at room temperature, the sections were incubated overnight at 4°C with the primary antibody diluted at 1:100. The slides were incubated for 60 min with biotinylated secondary antibody, and then incubated for 45 min with avidin-biotin-peroxidase complex (Vector Laboratories, Burlingame, CA). The immunoreaction was visualized by immersing the sections in 0.06 mM 3,3 0 -diaminobenzidine tetrahydrochloride containing 0.05% hydrogen peroxide. Finally, the sections were counterstained with hematoxylin. IGF1R protein expression was scored using the following algorithm: IHC score = R(I 9 PC), where I and PC represent the staining intensity and the percentage of tumor cells that stain at each intensity, respectively. Intensity was classified as 0 (none), 1 (weak), 2 (moderate), and 3 (strong).
Statistical Analyses
Because the distribution of the normalized IGF1R expression ratio among the 238 patients with lung adenocarcinoma showed a normal distribution (P = 0.0742, Kolmogorov-Smirnov analysis), its statistical significance in relation to various clinical and pathological variables was assessed using the chi-square test, Student's t test, or analysis of variance (ANOVA). The correlation between the normalized IGF1R expression ratio and the normalized EGFR expression ratio, and the correlation between the normalized IGF1R expression ratio and the IHC score of IGF1R protein expression were assessed using Pearson's correlation coefficient. Because a cut-off value of 121.5 in the normalized IGF1R expression ratio demonstrated the largest significance in relation to tumor differentiation and patient survival, lung adenocarcinomas were classified into two groups: IGF1R-high tumors if the normalized IGF1R expression ratio in a given tumor was 121.5 or more, and IGF1R-low tumors if the normalized IGF1R expression ratio in a given tumor was less than 121.5.
Overall survival (OS) was defined as the time from treatment initiation to date of death from any cause. Disease-free survival (DFS) was defined as the time from the initial treatment to date of onset of local recurrence or distant metastasis. The Kaplan-Meier method was used to estimate the probability of overall survival as a function of time, and differences in survival of the subgroups of patients were compared using a log-rank test. Multivariate analysis using a Cox proportional-hazards model was also performed using JMP software version 9.0.2 (SAS Institute, Cary, NC) to investigate the effect on survival. All P values were based on two-tailed statistical analysis, and P value \ 0.05 was considered to be statistically significant.
RESULTS
IGF1R Gene Expression and Its Relationship with EGFR Gene and IGF1R Protein Expressions in Lung Adenocarcinoma
Among the 238 patients with lung adenocarcinoma, the normalized IGF1R expression ratio varied widely, ranging S414 R. Kikuchi et al. from 1.2 to 868.9, with mean ± standard deviation of 160.0 ± 114.4 ( Fig. 1) . In total, 107 tumors (45.0%) were IGF1R-low and 131 (55.0%) were IGF1R-high. Regarding tumor differentiation, the normalized IGF1R expression ratio was 177.4 ± 104.8 in well-differentiated tumors, 147.3 ± 106.7 in moderately differentiated tumors, and 144.8 ± 147.4 in poorly differentiated tumors. The normalized IGF1R expression ratio was significantly lower in the moderately to poorly differentiated adenocarcinomas than in the well-differentiated adenocarcinomas (146.5 ± 120.0 versus 177.4 ± 104.8, P = 0.0388; Table 2 and Fig. 2a) . However, no significant difference was observed in the normalized IGF1R expression ratio with regard to tumor status, nodal status, pathological stage, smoking pack-years, gender, or age. The normalized IGF1R expression ratio was weakly but significantly correlated with the normalized EGFR expression ratio (r = 0.3813, P \ 0.0001; Fig. 2b) , and was also significantly correlated with the IHC score of IGF1R protein (r = 0.7163, P \ 0.0001; Fig. 2c ). The IGF1R protein was mainly expressed in a cytoplasmic pattern (Fig. 2d, e) .
Relationship between Survival of Patients with Lung Adenocarcinoma and IGF1R Gene Expression
Among all 238 patients, the 5-year OS rate was 63.2% in patients with IGF1R-low tumors and 76.1% in those with IGF1R-high tumors (Fig. 3a) . OS was significantly lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors (P = 0.0188). In particular, among 180 patients with stage I-II tumors, OS was significantly lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors (78.8% versus 88.0% 5-year survival, P = 0.0358; Fig. 3b ). However, no significant difference was observed in OS in patients with stage III-IV tumors (25.1% versus 37.0% 5-year survival, P = 0.3712; Fig. 3c ). For 124 patients with completely resected stage I-II tumors who received postoperative adjuvant therapy, OS was not significantly but slightly lower in patients with IGF1R-low tumors in comparison with those with IGF1R-high tumors (81.3% versus 85.1% 5-year survival, P = 0.2975; Fig. 3g ). On the other hand, for 54 patients with completely resected stage I-II tumors who did not receive adjuvant therapy, OS was significantly lower in patients with IGF1R-low tumors in comparison with those with IGF1R-high tumors (69.8% versus 92.8% 5-year survival, P = 0.0212; Fig. 3h) .
Among all 238 patients, the 5-year DFS rate was 49.2% in patients with IGF1R-low tumors and 64.6% in those with IGF1R-high tumors (Fig. 3d) , which was significantly different (P = 0.0084). Furthermore, among patients with stage I-II tumors, 5-year DFS was significantly lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors (60.7% versus 77.7%, P = 0.0098; Fig. 3e ). In contrast, no difference was observed in the DFS rate of patients with stage III-IV tumors (Fig. 3f) . Multivariate analysis using a Cox proportional-hazards model demonstrated that IGF1R status was a significant factor predicting OS of patients with lung adenocarcinoma (hazard ratio 1.800; P = 0.0321, Table 3 ) as well as smoking pack-years, differentiation, and pathological stage.
FIG. 1 Distribution of IGF1R expression in human lung adenocarcinomas
DISCUSSION
IGF1R is a membrane receptor-type tyrosine kinase. IGF receptors and insulin receptors (IR) evolved from an ancestral membrane receptor, and these receptors are widely expressed in normal human tissues. Both IGF1R and IR consist of two half-receptors, each comprising one extracellular a-subunit and one transmembrane b-subunit that possess tyrosine kinase activity. IGF1R is activated by IGF-1, IGF-2, and insulin. Activation of IGF1R results in autophosphorylation of tyrosines in its kinase domain to recruit adaptor proteins, which belong to the insulin receptor substrate family and Src homology and collagen domain proteins. The recruitment of these adaptor proteins then transduces signals via the PI3K-AKT and RAS/RAF/ MAPK pathways. 4, 5 The PI3K-AKT pathway is involved in cell survival, and the RAS/RAF/MAPK pathway regulates cellular proliferation. As a result, IGF1R is widely expressed in many human malignancies, and its expression has been reported to be involved in tumorigenesis and resistance against anti-EGFR therapy. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] However, controversy remains regarding the clinical significance of intratumoral IGF1R expression. Many early studies reported that high level of IGF1R expression was associated with aggressive behaviors of malignant tumors. Experimental studies have revealed that an antisense expression vector or a monoclonal antibody against IGF1R suppressed the growth of tumor cells. 23, 24 Furthermore, other experimental studies found that antibodies against IGF1R or its dominant negative receptor inhibited the metastatic potential of tumor cells. [25] [26] [27] In addition, clinical studies using immunohistochemistry also revealed that high level of IGF1R protein expression was associated with poor survival of patients with various types of cancer, including esophageal, gastric, colorectal, renal cell, and uterine cervical cancers. [6] [7] [8] [9] [10] As a result, IGF1R is considered to be a therapeutic target for cancer, and a number of IGF1R inhibitors, including small-molecule tyrosine kinase inhibitors and monoclonal antibodies against IGF1R, are currently being investigated in clinical trials. 4, 5 In contrast, other clinical studies reported that low level of IGF1R expression was associated with aggressive malignant behaviors and with poor prognosis in patients with colorectal cancer, gallbladder cancer, and soft tissue sarcoma. [28] [29] [30] Intriguingly, an experimental study also demonstrated that deletion of IGF1R accelerated the emergence of aggressive prostate cancer.
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Considering these conflicting results, the clinical significance of IGF1R expression in human cancer may be organ specific, and this possibility needs to be clarified for each type of human cancer. However, only a few studies have examined the clinical significance of IGF1R expression in lung cancer patients. [18] [19] [20] Therefore, the present study investigated the expression of IGF1R in human adenocarcinoma.
In the present study, IGF1R expression showed significant positive correlation to EGFR expression among patients with lung adenocarcinomas. Some in vitro studies have reported that IGF1R expression was associated with resistance to anti-EGFR therapy in NSCLC cell lines and that co-suppression of EGFR and IGF1R overcame resistance to anti-EGFR therapy. 16, 17 Our results suggested that IGF1R expression might also result in resistance of lung adenocarcinomas to anti-EGFR therapy in vivo, and cotargeting of EGFR and IGF1R would be worth trying in clinical settings.
The present study also demonstrated that low level of IGF1R expression is associated with poor prognosis in patients with lung adenocarcinoma. OS was lower in patients with IGF1R-low tumors than in those with IGF1R-high tumors, especially in the early stage of the disease. The resection margin status did not affect the OS of patients with stage I-II tumors, because 98.9% of the patients with stage I-II disease underwent complete resection. The survival disadvantage of stage I-II patients with IGF1R-low tumors was not attributed to inadequate adjuvant therapy, because adjuvant therapy was given more frequently in patients with IGF1R-low tumors than in those with IGF1R-high tumors [79.2% (61/77) versus 62.4% (63/ 101)], and the benefit of adjuvant therapy was greater for IGF1R-low tumors than for IGF1R-high tumors. In addition, expression of IGF1R was associated with differentiation of lung adenocarcinomas in the present study. Expression of IGF1R was lower in moderately to poorly differentiated adenocarcinomas in comparison with well-differentiated adenocarcinomas. These results suggested that low level of IGF1R expression is a useful marker for identifying dedifferentiated lung adenocarcinomas with poor prognosis.
In fact, insulin-like growth factor receptor signals were reported to be involved in development, differentiation, and maintenance of various normal tissues. [32] [33] [34] Furthermore, previous studies also revealed low IGF1R expression to be associated with dedifferentiation of various human cancers. 29, 35, 36 In addition, clinical studies have reported tumor differentiation to be a prognostic factor for survival of lung cancer patients. 37 The present study also demonstrated that tumor differentiation status was a significant factor that could be used to predict prognosis of patients with lung adenocarcinoma. On the other hand, previous clinical studies reported conflicting results about the clinical significance of IGF1R expression in lung cancer. [18] [19] [20] These discrepancies may be partly due to fact that these studies evaluated IGF1R protein expression levels using immunohistochemistry, whose accuracy is largely dependent on the quality of primary antibodies; for example, Dziadziuszko et al. reported that two different anti-IGF1R antibodies led to conflicting immunohistochemical staining results; the IHC score of one antibody was significantly correlated with IGF1R messenger RNA (mRNA) expression but the IHC score of another antibody was not. 20 In contrast, they reported that high IGF1R gene copy number was a positive prognostic factor of NSCLC. 20 In the present study, IGF1R gene expression was significantly correlated with IGF1R protein expression; therefore, the tendency to better prognosis in patients with IGF1R-high tumors was more reliable.
In conclusion, the present study demonstrated that expression of IGF1R was lower in moderately to poorly differentiated lung adenocarcinoma, and that low IGF1R expression was associated with poor prognosis in patients with lung adenocarcinoma, especially in the early stage of the disease. Although this prognostic impact of IGF1R gene expression was not obvious in patients with advanced disease, this may have been due to the relatively small number of patients and the variety of treatment modalities used in these patients. Further studies are required to clarify the role of IGF1R expression in patients with advanced lung cancer in order to determine the most effective chemotherapy and molecular-targeted therapy.
